Safecor Health Enhances Offerings with New Acquisition

Safecor Health Expands Its Business with Strategic Acquisition

Revitalized brand will offer a growing selection of generic unit-dose medicines to hospitals, health systems, institutions, long-term care facilities, GPOs, and pharmaceutical wholesalers and manufacturers

Safecor Health, recognized as a leader in pharmaceutical unit-dose repackaging and supply chain solutions, has made a significant move in expanding its offerings through the acquisition of the U.S. unit-dose packaging business from Viatris Inc., previously known as Unit Dose Laboratories (UDL). This strategic acquisition aligns with Safecor’s mission to enhance its product portfolio.

Mark Saxon, CEO of Safecor, expressed his enthusiasm about this acquisition, highlighting the strong brand recognition and capabilities that the UDL team brings to Safecor. He emphasized that this addition will bolster their ability to provide world-class packaging solutions, thereby benefiting manufacturers and health systems.

Founded in 1980, UDL emerged as a prominent player in delivering unit-dose generic medicines to various health institutions and long-term care facilities. Over the years, they have successfully expanded their product range to over 400 offerings, catering to diverse stakeholders including hospitals, health systems, and pharmaceutical wholesalers.

Kriss Spors, the Head of Site Operations for UDL, who will transition to Safecor, shared his excitement about joining the Safecor team. He believes that with combined efforts, they will enhance their service delivery to hospitals and healthcare professionals, ultimately benefiting the patients they serve.

With leadership totaling over 100 years of experience in unit-dose packaging, the UDL team is anticipated to play crucial roles within the Safecor organization, contributing to the growth of its generic unit-dose medications and packaging services.

Steve Fischbach, the Executive Vice Chairman of the Board and Co-Founder of Safecor Health, highlighted the cost-saving opportunities this acquisition brings, promising a more comprehensive selection of supplies tailored for hospital customers. He noted that existing solutions can significantly reduce drug costs, while fostering partnerships that optimize value in their supply chain operations.

UDL operates from state-of-the-art facilities equipped to provide custom packaging designs and in-house label solutions, ensuring a full-service experience for pharmaceutical manufacturers and wholesalers.

While the acquisition process is set to conclude in the first half of 2025, current customers and partners do not need to take immediate action. This transition aims to facilitate a seamless integration.

Safecor Health is also a proud member of the Vesey Street Capital Partners (VSCP) portfolio, a firm dedicated to enhancing its healthcare service businesses.

About Safecor Health

Established in 2008, Safecor Health is at the forefront of transforming unit-dose drug packaging and supply chain solutions for various healthcare providers, including hospitals and pharmaceutical manufacturers. The company excels in providing innovative and efficient unit-dose products aimed at improving healthcare delivery.

Safecor serves over 1,000 hospitals nationwide and has established relationships with a majority of the U.S. News & World Report's top-ranked hospitals. Through its advanced packaging centers, the company focuses on reducing drug costs, minimizing waste, and addressing drug shortages to better serve healthcare professionals and their patients.

About Vesey Street Capital Partners

Vesey Street Capital Partners specializes in the private equity market, primarily focusing on lower middle-market healthcare service businesses. The firm has successfully executed numerous transactions, deploying capital strategically to enhance business outcomes across its portfolio.

Frequently Asked Questions

What did Safecor Health acquire?

Safecor Health acquired the U.S. unit-dose packaging business from Viatris Inc., enhancing its capabilities in the pharmaceutical packaging industry.

What is the significance of the acquisition?

The acquisition will expand Safecor’s product offerings and improve service delivery to healthcare providers, ultimately benefiting patient care.

How many products did UDL offer?

UDL had a portfolio of over 400 unit-dose generic medicines aimed at hospitals, health systems, and long-term care facilities.

What role will the UDL team play in Safecor Health?

The UDL leadership team will play key roles in further developing Safecor's generic unit-dose medications and packaging services.

When is the acquisition expected to finalize?

The acquisition is projected to be finalized in the first half of 2025, with no immediate action required from customers.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.